Pascolizumab: Difference between revisions

Browse history interactively

← Previous edit

Content deleted Content added

VisualWikitext

@@ Line 1: / Line 1: @@
+{{Short description|Monoclonal antibody}}
 {{Drugbox
 | Verifiedfields = changed
-| verifiedrevid = 437188747
+| verifiedrevid = 458269502
 | image =
+<!-- Monoclonal antibody data -->
-<!--Monoclonal antibody data-->
 | type = mab
 | mab_type = mab
 | source = zu/o
 | target = [[Interleukin 4|IL-4]]
+<!-- Clinical data -->
-<!--Clinical data-->
 | tradename =
 | pregnancy_AU =
@@ Line 21: / Line 20: @@
 | legal_status =
 | routes_of_administration =
+<!-- Pharmacokinetic data -->
-<!--Pharmacokinetic data-->
 | bioavailability =
 | protein_bound =
@@ Line 28: / Line 26: @@
 | elimination_half-life =
 | excretion =
+<!-- Identifiers -->
+| CAS_number_Ref = {{cascite|changed|??}}
-<!--Identifiers-->
+| CAS_number = 331243-22-2
-| CAS_number_Ref = {{cascite|correct|??}}
-| CAS_number = <!-- blanked - oldvalue: 331243-22-2 -->
 | ATC_prefix = none
 | ATC_suffix =
 | PubChem =
+| IUPHAR_ligand = 7786
 | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank =
@@ Line 40: / Line 38: @@
 | UNII = N1IOA09R6A
 | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
-| ChemSpiderID = NA
+| ChemSpiderID = none
+<!-- Chemical data -->
-<!--Chemical data-->
 | chemical_formula =
 | molecular_weight =
 }}
-'''Pascolizumab''' is a [[humanize]]d [[monoclonal antibody]] for the treatment of [[asthma]].<ref>{{cite journal|pmid=12296858|year=2002|last1=Hart|first1=TK|last2=Blackburn|last3=Brigham-Burke|last4=Dede|last5=Al-Mahdi|last6=Zia-Amirhosseini|last7=Cook|title=Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma|volume=130|issue=1|pages=93–100|journal=Clinical and experimental immunology|doi=10.1046/j.1365-2249.2002.01973.x|first2=MN|first3=M|first4=K|first5=N|first6=P|first7=RM|pmc=1906490}}</ref> A Phase II [[clinical trial]] in patients with symptomatic [[glucocorticoid]] naive asthma has been conducted in 2001/2002.<ref>[http://www.clinicaltrials.gov/ct2/show/NCT00024544 ClinicalTrials.gov]</ref>
+'''Pascolizumab''' is a [[humanized monoclonal antibody]] for the treatment of [[asthma]].<ref>{{cite journal | vauthors = Hart TK, Blackburn MN, Brigham-Burke M, Dede K, Al-Mahdi N, Zia-Amirhosseini P, Cook RM | title = Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma | journal = Clinical and Experimental Immunology | volume = 130 | issue = 1 | pages = 93–100 | date = October 2002 | pmid = 12296858 | pmc = 1906490 | doi = 10.1046/j.1365-2249.2002.01973.x }}</ref> A Phase II [[clinical trial]] in patients with symptomatic [[glucocorticoid]] naive asthma was conducted in 2001/2002.<ref>{{ClinicalTrialsGov|NCT00024544|Pilot Study in Patients With Symptomatic Steroid-Naive Asthma}}</ref> Development was discontinued as it showed little benefit.<ref>{{cite journal | vauthors = Bice JB, Leechawengwongs E, Montanaro A| title = Biologic targeted therapy in allergic asthma| journal = Annals of Allergy, Asthma & Immunology| volume = 112 | issue = 2 | page = 108 - 115| year = 2014 | doi = 10.1016/j.anai.2013.12.013}}</ref>
-==References==
+== References ==
-{{reflist}}
+{{Reflist}}
+{{Immunosuppressants}}
-{{immunosuppressants}}
 {{Monoclonals for immune system}}
+{{Interleukin receptor modulators}}
+[[Category:Monoclonal antibodies]]
+[[Category:Experimental monoclonal antibodies]]
 {{monoclonal-antibody-stub}}
 {{antineoplastic-drug-stub}}